CHERIE SIMPSON: Open Payments
NPI 1720030307 · AUSTIN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,125 in 34 payments from 12 companies in 2025. Trend: 2023 $1,181 · 2024 $1,069 · 2025 $1,125
Food & beverage: $1,125
| Company | Payments | Amount |
|---|---|---|
| Axsome Therapeutics, Inc. | 6 | $239 |
| Lilly USA, LLC | 5 | $149 |
| Biogen, Inc. | 2 | $136 |
| Janssen Pharmaceuticals, Inc | 2 | $129 |
| Lundbeck LLC | 4 | $98 |
| ACADIA Pharmaceuticals Inc | 4 | $88 |
| Eisai Inc. | 3 | $80 |
| ABBVIE INC. | 2 | $65 |
| Otsuka America Pharmaceutical, Inc. | 2 | $54 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
Products named: Auvelity, REXULTI, SPRAVATO, KISUNLA, Leqembi, NUPLAZID, VRAYLAR, AMYVID.
Industry payments across TX — which companies pay providers there.
